comparemela.com

Latest Breaking News On - Marin kurs - Page 1 : comparemela.com

Amarin Applauds HealthyWomen's Citizen's Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event Seite 1

24.04.2024 - Citizen Petition Spotlights Risks for Patients on Drug Proven to Have No Benefit in Improving Cardiovascular Outcomes and Need for Urgent Regulatory Action to Protect PatientsDUBLIN, Ireland and BRIDGEWATER, N.J., April 24, 2024 (GLOBE NEWSWIRE) - . Seite 1

Nabil-abadir
Chief-medical-officer
Amarin-chart
Marin-kurs
Marin-aktie

New REDUCE-IT Analyses Show VASCEPA/VAZKEPA (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups

06.04.2024 - - Findings Presented on VASCEPA/VAZKEPA Utility in REDUCE-IT Patient Subgroups by Baseline High/Low Lp(a), LDL-C Levels - - Lp(a) Results Published Simultaneously in the Journal of the American College of Cardiology (JACC) – DUBLIN, . Seite 1

Dublin
Ireland
Nabil-abadir
Journal-of-the-american-college-cardiology
Nasdaq
Head-of-global-medical-affairs
Amarin-corporation
Major-adverse-cardiovascular-events
American-college
Chief-medical-officer
Global-medical-affairs
Amarin-chart

Research Evaluating Benefits of VASCEPA/VAZKEPA (icosapent ethyl) to be Presented at the American College of Cardiology's (ACC) Annual Scientific Session & Expo Seite 1

25.03.2024 - - Subgroup Analyses from REDUCE-IT and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting -    DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) - Amarin Corporation plc (NASDAQ:AMRN) . Seite 1

Michael-miller
Elliota-brinton
Nabil-abadir
Deepakl-bhatt
Head-of-global-medical-affairs-at-amarin
Chief-medical-officer
Global-medical-affairs
Available-april
Moderated-poster-theater
Amarin-chart
Marin-kurs
Marin-aktie

vimarsana © 2020. All Rights Reserved.